News

Oct 04th 2017

Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies


Sep 28th 2017

Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers


More news

#ThinkBigger

 
 
 

Wellington Partners
Life Sciences

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.

 

Focus

Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology.

Strong entrepreneurial teams, deep domain knowledge.

Disruptive, innovative tech addressing high unmet medical needs in large markets.

 

Scope

Europe, special circumstances US, leader in Germany.

Seed to late-stage, private companies most of the time.

Ticket sizes from €1m up to €10m over life of investment.

 

Funds

Managing and investing out of funds WP III and WP IV.

More than €200m AUM dedicated to Life Sciences.

Investment Team with strong clinical, scientific and operational backgrounds.